KLRK1 and neoplasm: A separate study from the Kaufman group showed that CARs generated against the NK-activating domain NKG2D greatly improves the anti-tumor activity in iPS-NKs by activating PLC-gamma, the Syk-vav1-Erk pathway, and the NK-κB pathway.